In recurrent GBM, NRP1 is down-regulated, indicating that disruption of the balance between VEGF-A and TGFβ signaling is a mechanism that promotes anti-angiogenic resistance in GBM [119]. The gene discussed is TGFB1; the disease is glioblastoma.